Sanofi India Posts Strong Q4 Results As Revenue Hits ₹4.72 Billion, Profit ₹1.03 Billion

The quarter’s outcome reflects Sanofi India’s resilience in a competitive market, reinforcing its position as a leading player in healthcare and pharmaceuticals. The company’s ability to balance revenue growth with profitability underscores its operational strength.

Quarterly Performance

Sanofi India reported consolidated revenue of ₹4.72 billion, supported by strong sales across therapeutic segments. Net profit stood at ₹1.03 billion, reflecting improved margins and disciplined financial management.

Market Significance

The results strengthen Sanofi India’s credibility in the pharmaceutical industry. With rising demand for healthcare solutions and expanding product portfolios, the company is well-positioned to capture growth opportunities and enhance investor confidence.

Future Outlook

Sanofi India aims to leverage innovation, expand its reach in key therapeutic areas, and continue investing in research and development to sustain growth momentum.

Key Highlights

• Consolidated revenue ₹4.72 billion in March quarter
• Net profit ₹1.03 billion reported
• Strong demand across therapeutic segments
• Focus on innovation and R&D for future growth

Sources: Reuters corporate filings, Sanofi India Ltd announcements, InvestyWise, Mint, Rediff MoneyWiz